SCHEMBL6922696

SCHEMBL6922696

CC1CN(C)Cc2nc3cc(-c4ccccn4)ccc3c(=O)n21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.41
TGFBR1 P36897 1/20 0.39
PDK1 Q15118 1/20 0.37
PDK2 Q15119 1/20 0.37
GSK3B P49841 1/20 0.37
DYRK1A Q13627 1/20 0.37
METAP2 P50579 1/20 0.37
GHSR Q92847 1/20 0.36
DRD2 P14416 1/20 0.35
MAPT P10636 1/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
TDP1 Q9NUW8 1/20 0.35
BRD4 O60885 2/20 0.35
METAP1 P53582 1/20 0.35
PRMT5 O14744 2/20 0.34
DHODH Q02127 1/20 0.34
WDR77 Q9BQA1 1/20 0.34
NSD2 O96028 1/20 0.34
CHRNB2 P17787 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6921512 0.87 CYP3A4 (0.42) CYP3A4TGFBR1PDK1PDK2GSK3B
SCHEMBL6922279 0.85 NPC1 (0.39) CYP3A4TGFBR1GSK3BDYRK1AMETAP2
SCHEMBL6922143 0.84 CYP3A4 (0.40) CYP3A4TGFBR1GSK3BDYRK1AMETAP2
SCHEMBL6921502 0.82 CYP3A4 (0.40) CYP3A4TGFBR1PDK1PDK2GSK3B
SCHEMBL6920968 0.81 NPC1 (0.42) CYP3A4TGFBR1GSK3BDYRK1AMETAP2
SCHEMBL6922987 0.81 NPC1 (0.43) CYP3A4TGFBR1GSK3BDYRK1AMETAP2
SCHEMBL9995013 0.80 POLB (0.47) NPC1RAB9ATDP1RIPK1
SCHEMBL6920486 0.79 NPC1 (0.41) CYP3A4TGFBR1GSK3BDYRK1AMETAP2
SCHEMBL6920430 0.78 CYP3A4 (0.40) CYP3A4TGFBR1GSK3BDYRK1AMETAP2
SCHEMBL14238872 0.78 CYP2C9 (0.39) CYP3A4TGFBR1GSK3BDYRK1AMETAP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110319380-A1 Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof SUNOVION PHARMACEUTICALS INC. (US) 2011-12-29 US disclosed
WO-2011075699-A2 COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. (US) 2011-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110319380-A1 Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof GRM5, GRM2, GRM1 CYP3A4 4447/4885TGFBR1 3543/4885PDK1 471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.